Cancer Subtypes and Systemic Antineoplastic Treatment Utilization Among Patients with Advanced Breast Cancer Across Large Community Health Systems in the US
Author(s)
Lorenzo R, Pomerantz D, Subramanian V, Tran M, Rioth M, Berry A, Walters S, Wolf F, Sommers C, Chen W, Wolfe T, Brown T
Syapse, San Francisco, CA, USA
OBJECTIVES: Community health systems (CHSs) play a large role in the care of patients with cancer with these systems treating over 50% of patients with cancer across the US. The cancer subtypes observed and systemic treatments used among patients with advanced breast cancer seen in these CHSs are not widely published. This analysis describes the cancer subtypes and systemic treatment utilization of these patients treated across a sample of CHSs. METHODS: A retrospective analysis was performed utilizing the Syapse Learning Health Network (SLHN), electronic medical record (EMR) derived database that collects data from multiple care settings that make up the US CHSs across 33 states, 450+ hospitals and 1,900+ community employed oncologists. Patients >18 yo at advanced breast cancer diagnosis (IIIB+) from January 1, 2017 through June 22, 2021 were identified from the SLHN using ICD-10 codes. Data utilized for this analysis included both structured (set EMR fields like sex, birth date) and unstructured EMR data (physician notes) validated by Syapse’s Certified Tumor Registrars and then descriptively summarized. RESULTS: 1,763 patients from the SLHN with advanced disease (stage IIIB+) were included in the analysis. 54% of these patients were HR+/HER2-, 24% HR-/HER2-,12% HR+/HER2+, 7% HR-/HER2+ and 3% were unknown. 1,445 patients received systemic treatment; in the 1L setting 31% received a cyclophosphamide containing regimen, 29% a doxorubicin containing regimen, 21% for paclitaxel, 17% for letrozole, 15% for anastrozole, 15% for trastuzumab, 15% for pertuzumab, 14% for docetaxel, 14% for carboplatin and 12% for a palbociclib containing regimen. CONCLUSIONS: HR+/HER2- patients were the most common breast cancer subtype within this sample of CHSs patients which roughly correlates to SEER statistics of breast cancer subtypes. Patients with advanced breast cancer treated in the SLHN were most likely to receive a cyclophosphamide or a doxorubicin-containing regimen. Further analysis is planned to understand treatment patterns by cancer subtype.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSA410
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Drugs, Oncology